Cincinnati Public Radio: Researchers Zeroing In On Blood Vessels to Prevent COVID 'Long-Haulers'

UC physicians discuss clinical trial designed to help COVID patients

Richard Becker, MD, and Duncan Hite, MD, both professors in the UC College of Medicine and UC Health physicians, spoke with WVXU reporter Ann Thompson about a phase 2 clinical trial underway at UC/UC Health to determine the safety and efficacy of the drug razuprotafib in treating COVID-19 patients. UC is one of 20 sites across the nation participating in the trial.

Researchers say this drug could possibly prevent "long-haulers syndrome." Razuprotafib is already used to treat diabetes and renal disease. By zeroing in on blood vessels to make them healthier, it's hoped COVID patients can benefit, too. Becker, director of the UC Heart, Lung and Vascular Institute, and Hite, director of medical critical care at UC Health, are part of a clinical trial conducted by Aerpio Pharmaceuticals.

Listen to the interview online.

Learn more about the clinical trial on UC’s website.

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.

Related Stories

1

High Court offers protections for therapy speech

April 5, 2026

Jennifer Bard, a professor in the Donald P. Klekamp College of Law and the UC Department of Internal Medicine, spoke with journalists about the US Supreme Court ruling granting first amendment protections for speech offered during therapy sessions.

3

UC design student works with sports greats in co-op

April 2, 2026

Spectrum News profiles UC College of Design, Architecture, Art, and Planning communication design student Jayden Balwally, who had an internship with the Oklahoma City Thunder and worked with the Heisman Trophy Trust and the College Football Playoff.